Nubeqa plus ADT improved rPFS in mHSPC throughout all illness volumes, reducing the danger of radiological development or loss of life by 46%.
For sufferers with metastatic hormone-sensitive prostate most cancers (mHSPC), efficacy outcomes had been improved following therapy with Nubeqa (darolutamide) together with androgen deprivation remedy (ADT) in contrast with placebo plus ADT no matter illness quantity, in line with findings from the section 3 ARANOTE trial.
Information from a subgroup evaluation of ARANOTE offered through the 2025 ASCO Genitourinary Most cancers Symposium demonstrated that sufferers with high-volume illness who obtained Nubeqa (315 sufferers) achieved a median radiological progression-free survival (rPFS) of 30.2 months in contrast with 19.2 months amongst those that obtained placebo (157 sufferers). Sufferers with low-volume illness achieved a median rPFS of not reached (NR) within the investigational arm (131 sufferers) versus NR within the management arm (66 sufferers).
“The section 3 ARASENS examine demonstrated a larger than 30% discount within the danger of loss of life with the mix of [Nubeqa] plus ADT and docetaxel, which has turn into an ordinary of take care of the therapy of sufferers with mHSPC,” Dr. Fred Saad stated throughout a presentation of the info. “In ARANOTE, [Nubeqa] plus ADT considerably improved rPFS, lowering the danger of radiological development or loss of life by 46%. Quantity of illness is a prognostic issue for sufferers with mHSPC and right here we report a post-hoc evaluation of ARANOTE to judge the efficacy and security of [Nubeqa] by illness quantity.”
Saad is the director of prostate most cancers analysis on the Montreal Most cancers Institute, a uro-oncologist within the Urology Division, and a full professor within the Division of Surgical procedure on the Centre Hospitalier de l’Université de Montréal in Canada.
Glossary:
Radiological progression-free survival (rPFS): the time from therapy initiation to radiographic illness development or loss of life.
ECOG efficiency standing of 0 to 2: a measure of a affected person’s every day functioning, the place 0 signifies full exercise, and a pair of signifies the flexibility to carry out self-care however not work.
Visceral metastases: most cancers that has unfold to organs such because the liver, lungs or mind.
Gleason Rating: a grading system that evaluates the aggressiveness of prostate most cancers based mostly on microscopic tumor look.
Total survival (OS): the time from prognosis or therapy begin to loss of life from any trigger.
Time to initiation of subsequent anticancer remedy: the period from therapy begin to the start of the following line of most cancers therapy.
Time to metastatic castration-resistant prostate most cancers (mCRPC): the time from preliminary therapy to the event of resistance to hormone remedy with metastases.
Time to prostate-specific antigen (PSA) development: the period till a confirmed rise in PSA ranges, indicating potential illness development.
Charges of undetectable PSA: the proportion of sufferers reaching PSA ranges beneath the detection threshold.
Time to ache development: the time till a clinically important worsening of ache associated to most cancers.
In November 2024, the FDA accepted a supplemental new drug software (sNDA) in search of the approval of Nubeqa plus ADT for the therapy of sufferers with mHSPC. The sNDA was supported by earlier knowledge from ARANOTE. Findings from ARANOTE offered through the 2024 ESMO Congress confirmed that no matter illness quantity sufferers who obtained Nubeqa plus ADT (446 sufferers) achieved a median rPFS of NR versus 25 months within the placebo arm (223 sufferers).
Diving Into the ARANOTE Trial and Baseline Traits
ARANOTE was a world, double-blind examine that enrolled sufferers with mHSPC who had an ECOG efficiency standing of 0 to 2. Sufferers had been stratified based mostly on the presence of visceral metastases (sure versus no) and receipt of prior native remedy (sure versus no). Eligible sufferers had been randomly assigned 2:1 to obtain Nubeqa at a dose of 600 milligrams twice every day or placebo, each together with ADT.
The first finish level was rPFS by central blinded evaluate. Secondary finish factors included general survival (OS), time to initiation of subsequent anticancer remedy, time to metastatic castration-resistant prostate most cancers (mCRPC), time to prostate-specific antigen (PSA) development, charges of undetectable PSA (lower than 0.2 ng/mL), time to ache development and security.
Within the post-hoc evaluation that Saad offered, sufferers had been evaluated based mostly on illness quantity per CHAARTED standards. Excessive-volume illness was outlined because the presence of visceral metastases and/or a minimum of 4 bone lesions with a minimum of one lesion past the vertebral our bodies and pelvis. Low-volume illness was outlined as not assembly the high-volume standards.
At baseline, the median age of the general affected person inhabitants was 70 years. Most sufferers had a Gleason rating of a minimum of 8 at preliminary prognosis (68.3%) and de novo metastasis at preliminary prognosis (72.5%). The examine additionally included sufferers with visceral metastases (12%), those that had obtained prior native remedy (17.9%), and people with an ECOG efficiency standing of 0 (49.8%). The median serum PSA stage at baseline was 21.3 ng/mL.
Additional Efficacy and Security Information from the Evaluation
Extra findings from the post-hoc evaluation confirmed that sufferers within the high- and low-volume teams skilled a delayed time to mCRPC with Nubeqa plus ADT versus placebo plus ADT, which was per the profit noticed within the general inhabitants. Sufferers with high-volume illness within the investigational and management arms achieved a median time to mCRPC of NR versus 12.4 months, respectively. Within the low-volume group, the median time to mCRPC was NR versus 19.8 months, respectively.
The addition of Nubeqa to ADT additionally led to a profit in contrast with placebo plus ADT throughout all secondary finish factors examined. The best advantages had been reported in time to initiation of subsequent systemic anticancer remedy in sufferers with low-volume illness, time to PSA development in sufferers with low-volume illness and time to PSA development in sufferers with high-volume illness.
“OS outcomes had been immature, however suggestive of a profit with [Nubeqa] versus placebo,” Saad famous.
Evaluable sufferers with high-volume illness within the Nubeqa arm (304 sufferers) had undetectable PSA ranges 24, 36 and 48 weeks after random task at charges of 44%, 48% and 50%, respectively; 55% of those sufferers achieved undetectable PSA at any time. Comparatively, sufferers within the placebo arm (148 sufferers) achieved undetectable PSA at charges of 11%, 13%, 14% and 16%, on the respective time factors.
Sufferers with low-volume illness who obtained Nubeqa (121 sufferers) additionally skilled undetectable PSA ranges at increased charges in contrast with those that obtained placebo (63 sufferers) on the 24- (72% versus 17%, respectively), 36- (78% versus 19%) and 48-week (79% versus 19%) time factors. Sufferers skilled undetectable PSA at any time at charges of 83% versus 25%, respectively.
When it comes to security, sufferers with high-volume illness who obtained Nubeqa (314 sufferers) or placebo (156 sufferers) each skilled any-grade treatment-emergent negative effects (TEAEs; 93% versus 91.7%, respectively), grade 3 (extreme) or 4 (life-threatening) TEAEs (31.2% versus 31.2%), critical TEAEs (28.3% versus 25.6%) and TEAEs main to check drug discontinuation (7.3% versus 8.3%). Sufferers with low-volume illness within the Nubeqa (131 sufferers) and placebo (65 sufferers) arms additionally skilled any-grade TEAEs (86.3% versus 86.2%), grade 3 or 4 TEAEs (29.8% versus 26.2%), critical TEAEs (12.2% versus 18.5%) and TEAEs main to check drug discontinuation (3.1% versus 10.8%).
“Efficacy outcomes with [Nubeqa] plus ADT had been improved versus placebo plus ADT no matter illness quantity,” Saad stated in conclusion. “[Nubeqa] plus ADT was nicely tolerated in each high-volume and low-volume subgroups with low therapy discontinuation charges per the general inhabitants and reconfirming the established tolerability of darolutamide. Sufferers with low-volume mHSPC had marked therapy efficacy with minimal therapy burden.”
References:
- “Darolutamide plus ADT in sufferers with metastatic hormone-sensitive prostate most cancers (mHSPC) by illness quantity: subgroup evaluation of the section 3 ARANOTE trial.” By Dr. Fred Saad, et al. J Clin Oncol.
- “Efficacy and security of darolutamide plus androgen-deprivation remedy (ADT) in sufferers with metastatic hormone-sensitive prostate most cancers (mHSPC) from the section III ARANOTE trial.” By Dr. Fred Saad, et al. Ann Oncol.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
